BEATW — HeartBeam, Inc.

HeartBeam (BEATW) Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Net Loss: $5.3 million, or $0.15 per share, consistent with the previous quarter and analyst expectations.
• Operating Cash Flow: Net cash used in operating activities was $3.2 million, an 8% decrease from the prior quarter, building on a 23% decrease in the previous quarter.
• Cash Position: As of September 30, 2025, cash and cash equivalents stood at $1.9 million.
• Focus on Cash Management: The company emphasized maintaining financial discipline while preparing for commercialization.

2. Strategic Updates and Business Highlights

• Product Overview: HeartBeam is developing a portable, cable-free ECG system capable of synthesizing a 12-Lead ECG, aimed at enhancing at-home heart health monitoring.
• FDA Clearances: Achieved foundational FDA 510(k) clearance in December 2024. Anticipating clearance for the 12-Lead ECG synthesis software by year-end 2025.
• Partnerships: Signed an agreement with HeartNexus for on-demand cardiologist services to interpret ECG readings, a critical component for the upcoming commercial launch.
• Ecosystem Development: Building a comprehensive ecosystem around the HeartBeam system, including automated assessments, integration with wearables, and patient engagement features.
• Intellectual Property: Secured three new patents, bringing the total to 24, and recognized as a leader in portable cardiac diagnostics.

3. Forward Guidance and Outlook

• Commercial Launch: Expected to begin early next year following FDA clearance. Initial focus on prominent concierge and preventive cardiology practices in Southern California and South Florida.
• Sales Strategy: Plans to adopt a subscription model for users, with an emphasis on user experience and retention.
• Market Penetration: Anticipated gradual rollout in 2026, with significant growth expected in the second half of the year as the business model is validated.

4. Bad News, Challenges, or Points of Concern

• Cash Constraints: The company is operating with a tight cash position, requiring careful monitoring and strategic funding to support growth and commercialization efforts.
• Regulatory Risks: Dependence on timely FDA clearance for the 12-Lead ECG synthesis software, which is crucial for the commercial launch.
• Market Entry Risks: Initial slow sales growth is expected as the company focuses on establishing workflows and user experience, with potential delays in scaling operations.

5. Notable Q&A Insights

• FDA Discussions: Management described ongoing interactions with the FDA as productive but did not provide specific details on the nature of inquiries.
• Market Launch Strategy: Plans to start with a small number of high-profile accounts to gather feedback before expanding into additional territories.
• Pricing Strategy: The company is considering a subscription model, with different pricing for symptomatic versus asymptomatic readings, although specific details are still being finalized.
• Manufacturing Confidence: The company expressed confidence in its manufacturing capabilities, utilizing off-the-shelf components to ensure scalability.
• Future Indications: Plans to pursue additional indications for myocardial infarction detection, with initial discussions already underway with the FDA.

Overall, HeartBeam is positioned at a critical juncture with its innovative ECG technology, aiming for a successful commercial launch while navigating financial and regulatory challenges.